Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Angina Pectoris/MI
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Angina Pectoris/MI
    Certain Biomarkers Have Limitations in Predicting Cardiovascular Events - (DGNews)
    Routine early angioplasty after fibrinolysis for acute myocardial infarction - (N Engl J Med)
    Some Stroke Survivors' Function Slowly Declines Over Time - (DGNews)
    Migraine With Aura Frequency Plays a Role in Risk of Stroke, MI - (DGNews)
    TopAbstracts in Angina Pectoris/MI 06/24/2009 - (DGNews)

    News archive

     Recent webcasts/CME - Angina Pectoris/MI
      Keys to Successful Outcomes from Anticoagulant and Antiplatelet Therapy: Addressing Medication Therapy Management Issues
      Cardiovascular Series: Guidelines for Anticoagulant and Antiplatelet Therapy in the Prevention and Treatment of Acute Coronary Syndrome: Incorporation into Clinical Practice
      Translating Evidence-Based Guidelines into Clinical Practice in the Management of Acute Coronary Syndrome
      Advancing the Standard of Care: Cardiovascular and Neurovascular Emergencies
      Anti-inflammatory and Anti-atherogenic Effects of Insulin

      Webcasts/CME archive

       Recent cases - Angina Pectoris/MI
        Giant Right Coronary Artery Aneurysm: Case Report and Literature Review
        Acute Myocardial Infarction and Pulmonary Embolism in a Young Man with Pernicious Anemia-Induced Severe Hyperhomocysteinemia
        Ultrasound In Evaluation of Post-Interventional Femoral Vein Obstruction: A Case Report
        Menstruation Angina: A Case Report
        Spontaneous Left Main Coronary Artery Dissection Complicated by Pseudoaneurysm Formation in Pregnancy: Role of CT Coronary Angiography

        Cases archive
          




        my personal edition > angina pectoris/mi > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Tirofiban Is as Effective as Abciximab for Lowering ST-Segment Elevation in STEMI Patients: Presented at SCAI

          By Bruce Sylvester

          CHICAGO -- April 2, 2008 -- Treatment with tirofiban resulted in noninferior ST-segment resolution compared with abciximab among patients undergoing angioplasty for ST-elevation myocardial infarction (STEMI).

          Investigators reported this finding on March 30 here at the Annual Scientific Sessions of the Society for Cardiovascular Angiography and Interventions (SCAI 2008), held in partnership with the American College of Cardiology Innovation in Intervention: i2 Summit.

          In a press briefing, lead investigator Marco Valgimigli, MD, PhD, Staff Cardiologist, University of Ferrara, Ferrara, Italy, presented the findings of the Multicentre Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY).

          "The results of this important trial show that in STEMI patients undergoing primary angioplasty, treatment with tirofiban results in similar clinical outcomes as well as improved safety, in terms of lower thrombocytopaenia, when compared to abciximab treatment."

          Briefing panel member, E. Magnus Ohman, MD, Professor of Medicine, Director, Program for Advanced Coronary Disease at Duke University School of Medicine in Durham, North Carolina, added, "this study is an important addition to our knowledge of optimal therapy in primary [percutaneous coronary intervention]."

          Abciximab infusion and uncoated stent implantation are currently used as complementary treatment strategies to reduce major adverse cardiac events in patients undergoing angioplasty for STEMI, according to Dr. Valgimigli and colleagues.

          The researchers used a 2-by-2 factorial design, randomising 745 STEMI patients at treatment centres in Italy, Spain, and Argentina to undergo primary angioplasty with infusion of abciximab (n=373) or tirofiban (n=372), with implantation of an uncoated (n=372) or sirolimus-eluting stent (n=373).

          Primary endpoints included (1) tirofiban's noninferiority to abciximab for cumulative ST-segment resolution, expressed as the proportion of subjects who achieved at least a 50% recovery within 90 minutes after intervention; and (2) whether the sirolimus-eluting stent is superior to uncoated-stent in terms of the composite of death from any cause, reinfarction, and clinically driven target vessel revascularisation in the first 8 months.

          Among 722 patients with interpretable electrocardiograms, at least 50% recovery from ST-elevation was observed in 85.3% of tirofiban subjects and 83.6% of abciximab patients (noninferiority P = .008).

          They also reported that the cumulative incidence of major adverse coronary events at 30 days or 8 months and bleeding rates did not differ between tirofiban and abciximab groups, but thrombocytopaenia was more common among abciximab subjects (4.0 vs 0.8%, P = .004).

          At 8 months, the researchers found that the primary clinical endpoint was achieved by 14.5% of patients in the uncoated stent group as compared with 7.8% in the sirolimus-stent group (P = .0039), attributable largely to a 69% relative risk reduction in target vessel revascularisation (from 10.2% to 3.2%; P = .0004).

          The findings of the phase 3, open-label, multinational study were published online in the Journal of the American Medical Association and will appear in the April 16 issue [Valgimigli M et al. Published online ahead of print March 30. doi:10.1001/jama.299.15.joc80026].

          Funding for the study was provided by Merck & Co., Inc. In January of 2008, Iroko Pharmaceuticals acquired all non-US rights to Aggrastat from Merck.


          [Presentation title: Comparison of Angioplasty With Infusion of Tirofiban or Abciximab and With Implantation of Sirolimus-Eluting or Uncoated Stents for the Treatment of Acute Myocardial Infarction. Abstract 2404-11]




        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send